Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…Abstract Number: 233 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
Background/Purpose: Use of tumor necrosis factor inhibitor (TNFi) drugs is common among patients with rheumatic disease who do not respond to conventional therapies. The aims…Abstract Number: 278 • 2018 ACR/ARHP Annual Meeting
The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study
Background/Purpose: Prescribing the first biologic for rheumatoid arthritis is an important decision for physicians, payers, and patients with costs and clinical implications. Our aim was…Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…Abstract Number: 1164 • 2018 ACR/ARHP Annual Meeting
Canadians’ Views about Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-Consumers and Researchers
Background/Purpose: Findings from health research using “big data” (large sets of routinely-collected healthcare data) have benefitted individual arthritis patients and society as-a-whole. However, growing…Abstract Number: 1754 • 2018 ACR/ARHP Annual Meeting
Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder belonging to a group of autoimmune inflammatory diseases characterized by…Abstract Number: 1755 • 2018 ACR/ARHP Annual Meeting
Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests as asthma, rhinosinusitis,…Abstract Number: 1963 • 2017 ACR/ARHP Annual Meeting
Association of Corticosteroid Exposure with Ophthalmologic Complications and Systemic Adverse Events in Non-Infectious Uveitis Patients Using Administrative Claims in the United States
Background/Purpose: Noninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders associated with significant visual impairment. Corticosteroids (CS) are typically the first-line drug therapy for…Abstract Number: 2593 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. Methods: Retrospective…Abstract Number: 2594 • 2017 ACR/ARHP Annual Meeting
Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard…Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…
ACR Meeting Abstracts